

**RECEIVED**

PTO SB 08 (2-92)

NOV 07 2001 Sheet 1 of 11

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION***(Use several sheets if necessary)*

Docket Number 377882001700

Application Number 09 802 376

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636

/635

Mailing Date October 24, 2001

TECH CENTER 1600-2900**U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
J3	1.	07/03/1984	4,458,006	Döenges et al.			
	2.	03/17/1987	4,650,675	Borel et al.			
	3.	07/18/1989	4,849,513	Smith et al.			
	4.	03/20/1990	4,910,300	Urdea et al.			
	5.	08/14/1990	4,948,882	Ruth			
	6.	05/14/1991	5,015,733	Smith et al.			
	7.	03/03/1992	5,093,232	Urdea et al.			
	8.	06/02/1992	5,118,800	Smith et al.			
	9.	06/02/1992	5,118,802	Smith et al.			
	10.	06/23/1992	5,124,246	Urdea et al.			
	11.	02/21/1995	5,391,723	Priest			
	12.	09/26/1995	5,453,496	Caruthers et al.			
	13.	01/16/1996	5,484,596	Hanna, Jr. et al.			
	14.	09/02/1997	5,663,153	Hutcherson et al.			
	15.	03/03/1998	5,723,335	Hutcherson et al.			
	16.	12/15/1998	5,849,719	Carson et al.			
	✓	17.	01/16/2001	6,174,872	Carson et al.		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
J3	18.	01/29/1992	0 468 520 A2, A3	Europe			
	19.	02/01/1996	WO 96/02555 A1	WIPO			
	20.	08/07/1997	WO 97/28259 A1	WIPO			
	21.	04/23/1998	WO 98/16247 A1	WIPO			
	22.	05/07/1998	WO 98/18810 A1	WIPO			

EXAMINER:

DATE CONSIDERED:

4/28/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered Include a copy of this form with next communication to applicant



RECEIVED

NOV 6 2001 PTO SB 08 (2-92)
Sheet 2 of 11

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001700

TECHCENTER 1600/2900

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636

1635

Mailing Date October 24, 2001

23.	09/03/1998	WO 98/37919 A1	WIPO			
24.	09/17/1998	WO 98/40100 A1	WIPO			
25.	11/26/1998	WO 98/52581 A1	WIPO			
26.	11/26/1998	WO 98/52962 A1	WIPO			
27.	12/10/1998	WO 98/55495 A2,A3	WIPO			
28.	12/10/1998	WO 98/55609 A1	WIPO			
29.	03/11/1999	WO 99/11275 A2,A3	WIPO			
30.	07/08/1999	WO 99/33488 A2,A3	WIPO			
31.	07/08/1999	WO 99/33868 A2,A3	WIPO			
32.	10/14/1999	WO 99/51259 A2,A3	WIPO			
33.	11/11/1999	WO 99/56755 A1	WIPO			
34.	12/09/1999	WO 99/62923 A2,A3	WIPO			
35.	02/10/2000	WO 00/06588 A1	WIPO			
36.	03/30/2000	WO 00/16804 A1	WIPO			
37.	04/20/2000	WO 00/21556 A1	WIPO			
38.	11/09/2000	WO 00/67023 A1	WIPO			
39.	02/22/2001	WO 01/12223 A2	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
93	40	Asanuma, H. et al., (1995) "Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration" <i>Vaccine</i> 13:3-5.
	41	Agrawal et al. (1986). "Efficient methods for attaching non-radioactive labels to the 5' ends of synthetic oligodeoxyribonucleotides." <i>Nucleic Acids Res.</i> 14:6227-6245.
	42	Ahmeida, E.T.S. Ben, (1993). "Immunopotential of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice." <i>Vaccine</i> 11(13):1302-1309.

EXAMINER:

DATE CONSIDERED:

11/28/03

EXAMINER Initials If citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

RECEIVED

NOV 07 2001
PTO SB 08 (2-92)
Sheet 3 of 11

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001700

Application Number 00/000000

Applicant

Gary VAN NEST and Stephen LUCK

Filing Date March 9, 2001

Group Art Unit 1636

1635

Mailing Date October 24, 2001

- | | | |
|-----|-----|---|
| 73 | 43. | Atherton et al. (1981). "Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method." <i>Hoppe-Seylers Z. Physiol. Chem.</i> 362:833-839. |
| 717 | 44. | Ballas et al. (1996). "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA." <i>J Immunol.</i> 157:1840-1845. |
| | 45. | Benoit et al. (1987). "Peptides. Strategies for antibody production and radioimmunoassays." <i>Neuromethods</i> 6:43-72. |
| | 46. | Bischoff et al. (1987). "Introduction of 5'-terminal functional groups into synthetic oligonucleotides for selective immobilization." <i>Analytical Biochemistry</i> 164:336-344. |
| | 47. | Blanks et al. (1988). "An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins." <i>Nucleic Acids Res.</i> 16:10283-10299. |
| | 48. | Boujrad et al. (1993). "Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor." <i>Proc. Natl. Acad. Sci. USA</i> 90:5728-5731. |
| | 49. | Branda et al. (1993). "Immune stimulation by an antisense oligomer complementary to the <i>rev</i> gene of HIV-1." <i>Biochem. Pharmacol.</i> 45:2037-2043. |
| | 50. | Branda et al. (1996). "Amplification of antibody production by phosphorothioate oligodeoxynucleotides." <i>J. Lab. Clin. Med.</i> 128:329-338. |
| | 51. | Braun et al. (1988). "Immunogenic duplex nucleic acids are nuclease resistant." <i>J. Immunol.</i> 141:2084-2089. |
| | 52. | Brazolot Millan et al. (1998) "CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice." <i>Proc. Natl. Acad. Sci. USA</i> 95:15553-15558. |
| | 53. | Breiteneder et al. (1989). "The gene coding for the major birch pollen allergen <i>Betv1</i> is highly homologous to a pea disease resistance response gene." <i>EMBO J.</i> 8:1935-1938. |
| | 54. | Broide et al. (1998). "Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice." <i>J. Immunol.</i> 161:7054-7062. |
| | 55. | Broide et al. (1999). "DNA-based immunization for asthma." <i>Int. Arch. Allergy Immunol.</i> 118:453-456. |
| | 56. | Carson et al. (1997). "Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination." <i>J. Exp. Med.</i> 186:1621-1622. |
| | 57. | Chace et al. (1997). "Bacterial DNA-induced NK cell IFN- γ production is dependent on macrophage secretion of IL-12." <i>Clin. Immunol. and Immunopathol.</i> 84:185-193. |
| ✓ | 58. | Chaturvedi et al. (1996). "Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages." <i>Nucleic Acids Res.</i> 24:2318-2323. |

EXAMINER:

DATE CONSIDERED:

4/23/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

NOV 07 2001 PTO SB 08 (2-92)

Sheet 4 of 11

Form PTO-1449		Docket Number 377882001700	TECH CENTER 1600-2900
INFORMATION DISCLOSURE TRADemark OFFICE		Applicant Gary VAN NEST and Stephen LUCK	
(Use several sheets if necessary)		Filing Date March 9, 2001	Group Art Unit 1636 1635
		Mailing Date October 24, 2001	

73	59.	Chen et al. (1999). "Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs," <i>Vaccine</i> 17:653-659.
	60.	Chu et al. (1997). "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186:1623-1631.
	61.	Chua et al. (1988). "Sequence analysis of cDNA coding for a major house dust mite allergen, <i>Der p 1</i> homology with cysteine proteases," <i>J. Exp. Med.</i> 167:175-182.
	62.	Chua et al. (1990). "Expression of <i>Dermatophagoides pteronyssinus</i> allergen, <i>Der p II</i> , in <i>Escherichia coli</i> and the binding studies with human IgE," <i>Int. Arch. Allergy Appl. Immunol.</i> 91:124-129.
	63.	Connolly, Bernard A. (1985). "Chemical synthesis of oligonucleotides containing a free sulphydryl group and subsequent attachment of thiol specific probes," <i>Nucleic Acids Res.</i> 13:4485-4502.
	64.	Connolly, Bernard A. (1987). "The synthesis of oligonucleotides containing a primary amino group at the 5'-terminus," <i>Nucleic Acids Res.</i> 15:3131-3139.
	65.	Corey et al. (1987). "Generation of a hybrid sequence-specific single-stranded deoxyribonuclease," <i>Science</i> 238:1401-1403.
	66.	Cowdery et al. (1996). "Bacterial DNA induces NK cells to produce IFN- γ <i>in vivo</i> and increases the toxicity of lipopolysaccharides," <i>J. Immunol.</i> 156:4570-4575.
	67.	de Martino et al. (1999). "Low IgG3 and high IgG4 subclass levels in children with advanced human immunodeficiency virus-type 1 infection and elevated IgE levels," <i>Ann. Allergy Asthma Immunol.</i> 83:160-164.
	68.	Elkins et al., (1999) "Bacterial DNA comprising CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria" <i>J. Immunol.</i> 162:2291-2298.
	69.	Elsayed et al. (1991). "The structural requirements of epitopes with IgE binding capacity demonstrated by three major allergens from fish, egg and tree pollen," <i>Scand. J. Clin. Lab. Invest.</i> 51(Suppl.204):17-31.
	70.	Fornadley, John (1998). "Allergy immunotherapy," <i>Otolaryngol. Clin. North Am.</i> 31:111-127.
	71.	Gao et al., (1995). "Circularization of oligonucleotides by disulfide bridge formation," <i>Nucleic Acids Res.</i> 23(11):2025-2029.
✓	72.	Geoghegan et al. (1992). "Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine," <i>Bioconjug. Chem.</i> 3:138-146.

EXAMINER:	DATE CONSIDERED: 4/23/03
EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



RECEIVED

NOV 6 7 2001

PTO SB 08 (2-92)

Page 5 of 11

TECH CENTER 1600-2900

Form PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)	Docket Number 377882001700	
	Applicant Gary VAN NEST and Stephen TUCK	
	Filing Date March 9, 2001	Group Art Unit 1636 / 6-55
	Mailing Date October 24, 2001	

73.	Godard et al. (1995) "Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylecyanoacrylate) nanoparticles" <i>Eur. J. Biochem.</i> 232:404-410.
74.	Goodechild, John (1990). "Conjugates of oligonucleotides and modified oligonucleotides: A review of their synthesis and properties" <i>Bioconjug. Chem.</i> 1(3):165-187.
75.	Govorkova and Smirnov (1997). "Cross-protection of mice immunized with different influenza A (H2) strains and challenged with viruses of the same HA subtype," <i>Acta Virol.</i> 41:251-257.
76.	Grabarek et al., "Zero-length crosslinking procedure with the use of active esters" (1990) <i>Anal. Biochem.</i> 185:131-135
77.	Gramzinski et al., "Immune response to a hepatitis B DNA vaccine in <i>aotus</i> monkeys: A comparison of vaccine formulation, route, and method of administration" (1998) <i>Mol. Med.</i> 4:109-118
78.	Granoff, Dan M. (1993). "Effect of immunity to the carrier protein on antibody responses to <i>Haemophilus influenzae</i> type b conjugate vaccines," <i>Vaccine</i> 11(1):S46-S51.
79.	Haralambidis et al. (1990). "The synthesis of polyamide-oligonucleotide conjugate molecules," <i>Nucleic Acids Res.</i> 18:493-499.
80.	Haralambidis et al. (1990). "The preparation of polyamide-oligonucleotide probes containing multiple non-radioactive labels," <i>Nucleic Acids Res.</i> 18:501-505.
81.	Horner et al. (1998). "Rapid communication: Immunostimulatory DNA is a potent mucosal adjuvant," <i>Cell Immunol.</i> 190:77-82.
82.	Jäger et al. (1988). "Oligonucleotide <i>N</i> -alkylphosphoramidates: Synthesis and binding to polynucleotides," <i>Biochem.</i> 27:7237-7246.
83.	Jakob et al. (1998). "Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA," <i>J. Immunol.</i> 161:3042-3049.
84.	Kataoka et al. (1992). "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>mycobacterium bovis</i> BCG," <i>Jpn. J. Cancer Res.</i> 83:244-247.
85.	Kikuta, K. et al., (1990) "Cross-protection against influenza B type virus infection by intranasal inoculation of the HA vaccines combined with cholera toxin B subunit <i>Vaccine</i> 8:595-599
86.	Kimura et al. (1994). "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN," <i>J. Biochem. (Tokyo)</i> 116:991-994.
87.	Kline et al. (1997). "Immune redirection by CpG oligonucleotides conversion of a Th2 response to a Th1 response in a murine model of asthma," <i>J. Invest. Med.</i> 45(3):282A.

EXAMINER:	DATE CONSIDERED: 4/27/02
EXAMINER Initial if citation considered whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	



RECEIVED

NOV 6 7 2001 PTO SB 08 (2-92)
Sheet 6 of 11

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary.)

Docket Number 377882001700

TECH CENTER 1500/2900

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636 / 653

Mailing Date October 24, 2001

88. Klinman et al. (1996). "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ ," *Proc. Natl. Acad. Sci. USA* 93:2879-2883.
89. Klinman et al., (1997). "Contribution of CpG motifs to the immunogenicity of DNA vaccines," *J. Immunol.* 158:3635-3639.
90. Kodihalli et al., (1997). "Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin," *J. Virol.* 71(5):3391-3396.
91. Kovarik et al. (1999). "CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming," *J. Immunol.* 162:1611-1617.
92. Kremsky et al. (1987). "Immobilization of DNA via oligonucleotides containing an aldehyde or carboxylic acid group at the 5' terminus," *Nucleic Acids Res.* 15:2891-2909.
93. Krieg, Arthur M. (1996). "Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA," *Trends in Microbiology* 4:73-77.
94. Krieg, Arthur M. (1998). "Leukocyte stimulation by oligodeoxynucleotides" Chapter 24 in *Applied Antisense Oligonucleotide Technology*. C.A. Stein et al. eds. Wiley-Liss, Inc.: pp. 431-448.
95. Krieg et al. (1989). "A role for endogenous retroviral sequences in the regulation of lymphocyte activation," *J. Immunol.* 143:2448-2451.
96. Krieg et al. (1995). "CpG motifs in bacterial DNA trigger direct B-cell activation" *Nature* 374:546-549.
97. Krieg et al. (1996). "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs," *Antisense & Nucleic Acid Drug Dev.* 6:133-139.
98. Krieg et al., (1998). "The role of CpG dinucleotides in DNA vaccines" *Trends Microbiol.* 6:23-27
99. Krieg et al., "CpG DNA induces sustained IL-12 expression in vivo and resistance to *listeria monocytogenes* challenge" (1998) *J. Immunol.* 161:2428-2434
100. Krieg et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs" (1998) *Proc. Natl. Acad. Sci. USA* 95:12631-12636
101. Krieg et al., (1999) "CpG DNA: a novel immunomodulator" *Trends Microbiol.* 7(2):64-65.
102. Latimer et al., "Specificity of monoclonal antibodies produced against phosphorothioate and ribo modified DNAs" (1995) *Mol. Immunol.* 32:1057-1064
103. Lea et al., "Cloning and sequencing of cDNAs encoding the human sperm protein, Sp17" (1996) *Biochim. Biophys. Acta* 1307:263-266

EXAMINER:

DATE CONSIDERED:

EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant



RECEIVED

NOV 07 2001

PTO SB 08 (2-92)

Page 7 of 11

TECH CENTER 1600/2900

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 377882001700	Application Number 09/023,378
	Applicant Gary VAN NEST and Stephen LUCK	
	Filing Date March 9, 2001	Group Art Unit 1636 / 63
	Mailing Date October 24, 2001	

104.	Leclerc et al., (1997) "The preferential induction of a TH1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA" <i>Cell. Immunol.</i> 179:97-106.
105.	Liang, Hua et al. (1996). "Activation of human B cells by phosphoroghoiate oligodeoxynucleotides." <i>J. Clin. Invest.</i> 98(5):1119-1129.
106.	Lipford et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines" (1997) <i>Eur. J. Immunol.</i> 27:3420-3426.
107.	Lipford et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants" (1997) <i>Eur. J. Immunol.</i> 27:2340-2344
108.	Liu et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor" (1998) <i>Blood</i> 92:3730-3736
109.	Macfarlane et al., "Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step" (1997) <i>Immunology</i> 91:586-593
110.	Malley, Arthur, "The immune response of offspring mice from mothers immunized during pregnancy with protein antigens" (1989) <i>J. Reprod. Immunol.</i> 16:173-186
111.	Manzel et al., (1999) "Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide" <i>Antisense Nucl. Acid Drug Dev.</i> 9:459-464.
112.	Martin-Orozco et al., "Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences" (1999) <i>Intl Immunol.</i> 11(7):1111-1118
113.	Mbawuike et al., "Influenza: A subtype cross-protection after immunization of outbred mice with a purified chimeric NS ₁ /HA ₂ influenza virus protein" (1994) <i>Vaccine</i> 12(14):1340-1348
114.	McCluskie et al., "Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice" (1998) <i>J. Immunol.</i> 161(9):4463-4466
115.	Miller et al., "Syntheses and properties of adenine and thymine nucleoside alkyl phosphotriesters, the neutral analogs of dinucleoside monophosphates" (1971) <i>JACS</i> 93:6657-6665
116.	Mitragotri et al., "Ultrasound-mediated transdermal protein delivery" (1995) <i>Science</i> 269:850-853
117.	Mojcik et al., "Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF <i>env</i> causes immune effects <i>in vivo</i> in a sequence-specific manner" (1993) <i>Clin. Immunol. and Immunopathol.</i> 67:130-136

EXAMINER:	DATE CONSIDERED: 4/29/03
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



RECEIVED

NOV 07 2001 PTO SB 08 (2-92)

Sheet 8 of 11

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 37882001700

TECH CENTER 1600/2800

Applicant

Gary VAN NEST and Stephen LUCK

Filing Date March 9, 2001

Group Art Unit 1636 / 635


Mailing Date October 24, 2001

118. Moldoveanu et al., "CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus" (1998) *Vaccine* 16:1216-1224
119. Nelson et al. (1989) "A new and versatile reagent for incorporating multiple primary aliphatic amines into synthetic oligonucleotides" *Nucleic Acids Res.* 17(18):7179-7186.
120. Nelson et al., "N3'→P5' oligodeoxyribonucleotide phosphoramidates: A new method of synthesis based on a phosphoramidite amino-exchange reaction." (1997) *J. Org. Chem.* 62:7278-7287.
121. O'Shannessy et al., "Specific conjugation reactions of the oligosaccharide moieties of immunoglobulins" (1985) *J. Applied Biochem.* 7:347-355
122. Pertmer et al., "Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery" (1996) *J. Virol.* 70:6119-6125
123. Peyrottes et al., "Oligodeoxynucleoside phosphoramidates (P-NH₂): synthesis and thermal stability of duplexes with DNA and RNA targets" (1996) *Nucleic Acids Res.* 24:1841-1848
124. Pisetsky, David S., "The immunologic properties of DNA" (1996a) *J. Immunol.* 156:421-423
125. Pisetsky, David S., "Immune activation by bacterial DNA: A new genetic code" (1996b) *Immunity* 5:303-310
126. Pisetsky et al., "Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus" (1994) *Life Sci.* 54:101-107
127. Pisetsky et al., "Immunological properties of bacterial DNA" DNA vaccines: A new era in vaccinology" (1995) *Ann. N.Y. Acad. Sci.* 772:152-163
128. Rafnar et al., "Cloning of *Amb a I* (antigen E), the major allergen family of short ragweed pollen" (1991) *J. Biol. Chem.* 266:1229-1236
129. Raz et al., "Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses" (1994) *Proc. Natl. Acad. Sci. USA* 91:9519-9523
130. Raz et al., "Preferential induction of a Th₁ immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization" (1996) *Proc. Natl. Acad. Sci. USA* 93:5141-5145
131. Redford et al., "Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides" (1998) *J. Immunol.* 161:3930-3935
132. Rogers et al., "Recombinant *Fel d I*: Expression, purification, IgE binding and reaction with cat-allergic human T cells" (1993) *Mol. Immunol.* 30:559-568
133. Roget et al., "Synthesis and use of labelled nucleoside phosphoramidite building blocks bearing a reporter group: biotinyl, dinitrophenyl, pyrenyl and dansyl" (1989) *Nucleic Acids Res.* 17:7643-7651

EXAMINER:

DATE CONSIDERED: 4/12/01

EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant



RECEIVED

NOV 07 2001 PTO SB 08 (2-92)

Sheet 9 of 11

Form PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001700

TECHCENTER 1600/2900

Applicant

Gary VAN NEST and Stephen LUCK

Filing Date March 9, 2001

Group Art Unit 1636


Mailing Date October 24, 2001

134. Romagnani, S. (2000) "T-cell subsets (Th1 versus Th2) *Ann. Allergy Asthma Immunol.* 85:9-18.
135. Roman et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants" (1997) *Nature Medicine* 3:849-854
136. Ruth, Jerry L., "Oligodeoxynucleotides with reporter groups attached to the base" (1991) *Oligonucleotides and Analogues: A Practical Approach*, Eckstein, ed., IRL Press, pp. 255-282
137. Sato et al., "Immunostimulatory DNA sequences necessary for effective intradermal gene immunization" (1996) *Science* 273:352-354
138. Schacht et al., (1996) "Biomedical applications of degradable polyphosphazenes" *Biotechnol. Bioeng.* 52:102-108.
139. Scherle et al., "Functional analysis of influenza specific helper T cell clones *in vivo*" (1986) *J. Exp. Med.* 164:1114-1128
140. Scherle et al., "Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones *in vivo*" (1988) *Proc. Natl. Acad. Sci. USA* 85:4446-4450
141. Schultz et al., "Oligo-2'-fluoro-2'-deoxynucleotide N3'→P5' phosphoramidates: synthesis and properties" (1996) *Nucleic Acids Res.* 24:2966-2973
142. Schwartz et al., "CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract" (1997) *J. Clin. Invest.* 100:68-73
143. Shimada et al., "In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG" (1986) *Jpn. J. Cancer Res.* 77:808-816
144. Sinha et al., "Oligonucleotides with reporter groups attached to the 5'-terminus" (1991) *Oligonucleotide Analogues: A Practical Approach*, Eckstein, ed., IRL Press, pp. 185-210
145. Sonehara et al., "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon" (1996) *J. Interferon and Cytokine Res.* 16:799-803
146. Sparwasser et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock" (1997) *Eur. J. Immunol.* 27:1671-1679
147. Spiegelberg et al., "Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides" (1998) *Allergy* 53:93-97
148. Spiegelberg et al., "Inhibition of allergic inflammation in the lung by plasmid DNA allergen immunization" (1999) *Pediatric Pulmonology Suppl.* 18:118-121
149. Stacey et al., "Macrophages ingest and are activated by bacterial DNA" (1996) *J. Immunol.* 157:2116-2122

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



RECEIVED

PTO SB 08 (2-92)

NOV 07 2001 Sheet 10 of 11

Form PTO-1449

INFORMATION DISCLOSURE CARD
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001700

Application Number 09 802,376

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636

Mailing Date October 24, 2001

150	Staros et al., "Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions" (1986) <i>Anal. Biochem.</i> 156:220-222.
151	Stein et al., "Chapter 11: Non-antisense effects of oligodeoxynucleotides" (1997) <i>Antisense Technology</i> , C. Lichtenstein and W. Nellen, eds., IRI, Press, pp. 241-264.
152	Stirchak et al., "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages" (1989) <i>Nucleic Acids Res.</i> 17:6129-6141
153	Tamura et al., "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine" (1992) <i>Eur. J. Immunol.</i> 22:477-481
154	Tamura et al., "Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice" (1994) <i>Vaccine</i> 12:310-316
155	Tokunaga et al., "Synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG induce interferons and activate natural killer cells" (1992) <i>Microbiol. Immunol.</i> 36:55-66
156	Tung et al., "Preparation of oligonucleotide-peptide conjugates" (1991) <i>Bioconjug. Chem.</i> 2:464-465
157	Wang et al., "Circular RNA oligonucleotides. Synthesis, nucleic acid binding properties, and a comparison with circular DNAs" (1994) <i>Nucleic Acids Res.</i> 22:2326-2333
158	Warner et al., "Laboratory methods. Construction and evaluation of an instrument for the automated synthesis of oligodeoxyribonucleotides" (1984) <i>DNA</i> 3:401-411
159	Weeratna et al. (1998) "Brief Communication: Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides" <i>Antisense & Nucleic Acid Drug Development</i> 8:351-356.
160	Weiner et al., "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization" (1997) <i>Proc. Natl. Acad. Sci. USA</i> 94:10833-10837
161	Widhe, M. et al. (1998). "IgG subclasses in lyme borreliosis: A study of specific IgG subclass distribution in an interferon- γ -predominated disease." <i>Scand. J. Immunol.</i> 47:575-581.
162	Wooldridge et al., "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma" (1997) <i>Blood</i> 89:2994-2998
163	Yamamoto et al., "Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity" (1992) <i>J. Immunol.</i> 148:4072-4076

EXAMINER:

DATE CONSIDERED: 4/1/03

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

NOV 07 2001

PTO SB 08 (2-92)

11 of 11

TECH CENTER 1600/2900

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 377882001700

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636

635

Mailing Date October 24, 2001

- 03
- | | |
|------|---|
| 164. | Yamamoto et al. (1994) "Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length" <i>Antisense Research and Development</i> 4:119-122. |
| 165. | Yamamoto et al., "Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes <i>in vitro</i> " (1994) <i>Jpn. J. Cancer Res.</i> 85:775-779 |
| 166. | Yanagawa et al., "Analysis of superhelical structures of nucleic acid-lipid conjugates by image processing" (1988) <i>Nucleic Acids Symp. Series</i> 19:189-192. |
| 167. | Yi et al. (1996) "IFN- γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides" <i>J. Immunol.</i> 156:558-564 |
| 168. | Yi et al., "CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I κ B α and I κ B β and sustained activation of nuclear factor- κ B/c-Rel" (1998) <i>J. Immunol.</i> 160:1240-1245 |
| 169. | Yi et al., "CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species" (1998) <i>J. Immunol.</i> 160:4755-4761 |
| 170. | Yi et al., "CpG oligodeoxynucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry" (1998) <i>J. Immunol.</i> 160:5898-5906 |
| 171. | Yi et al., "Cutting edge: Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA" (1998) <i>J. Immunol.</i> 161:4493-4497 |
| 172. | Zhao et al., "Effect of different chemically modified oligodeoxynucleotides on immune stimulation" (1996) <i>Biochem. Pharmacol.</i> 51:173-182 |
| 173. | Zon, Gerald, "Oligonucleoside phosphorothioates" Protocols for Oligonucleotides and Analogs, Chapter 8 in <i>Methods in Molecular Biology</i> , Volume 20 (1993) pp. 165-189 |
| 174. | Zimmermann et al., "Cutting edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis" (1998) <i>J. Immunol.</i> 3627-3630 |
| 175. | Zuckermann et al., "Efficient methods for attachment of thiol specific probes to the 3'-ends of synthetic oligodeoxyribonucleotides" (1987) <i>Nucleic Acids Res.</i> 15:5305-5321 |

EXAMINER:

DATE CONSIDERED:

4/29/03

EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered Include a copy of this form with next communication to applicant

Form PTO-1449

MAR 2 2002

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 37882001300

Application Number 09802376

Applicant

Gary VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group Art Unit 1636

Mailing Date March 12, 2002

TECHNICAL 1600 2903

MAR 2 2002

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
JZ	1.	07/03/1984	4,458,066	Caruthers et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
JZ	2. *	09/20/2001	WO 01/68077 A2	WIPO			
	3. *	09/20/2001	WO 01/68103 A2	WIPO			
	4. *	09/20/2001	WO 01/68116 A2	WIPO			
	5. *	09/20/2001	WO 01/68143 A2	WIPO			
	6. *	09/20/2001	WO 01/68144 A2	WIPO			
	7. *	10/18/2001	WO 01/76642 A1	WIPO			
	8. *	09/20/2001	WO 01/68078 A2	WIPO			
	9. *	09/20/2001	WO 01/68117 A2	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title

EXAMINER:

DATE CONSIDERED:

EXAMINER Initial of citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

Form PTO-1449

Docket Number 378820001, 700

Application Number 09/802,376

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

GARY VAN NEST and Stephen TUCK

Filing Date March 9, 2001

Group 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100

Mailing Date December 4, 2002

DEC 11 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
J3	1.	01/04/2001	WO 01/00231	WIPO			
J3	2.	03/08/2001	WO 01/15726	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title

EXAMINER

DATE CONSIDERED:

EXAMINER Initial if citation considered, whether or not the citation conforms with MPEP 609 Draw a line through the citation if not in conformance and not considered Include a copy of this form with next communication to applicant